Solithromycin, a novel macrolide, does not prolong cardiac repolarization: a randomized, three-way crossover study in healthy subjects

SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia

(2016) Thomas M. File et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)

(2016) Carlos M Barrera et al.   LANCET INFECTIOUS DISEASES

The Role of Macrolide Antibiotics in Increasing Cardiovascular Risk

(2015) Yun-Jiu Cheng et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Randomized, Double-Blind, Multicenter Phase 2 Study Comparing the Efficacy and Safety of Oral Solithromycin (CEM-101) to Those of Oral Levofloxacin in the Treatment of Patients with Community-Acquired Bacterial Pneumonia

(2013) David Oldach et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition

(2013) Y Kobayashi et al.   BRITISH JOURNAL OF PHARMACOLOGY

Antibiotic-induced Cardiac Arrhythmias

(2013) Elsayed Abo-Salem et al.   Cardiovascular Therapeutics

Creation of a Knowledge Management System for QT Analyses

(2010) Christoffer W. Tornøe et al.   JOURNAL OF CLINICAL PHARMACOLOGY